Retatrutide
01 Summary
A once-weekly “triple agonist” that adds the glucagon receptor to the GLP-1 and GIP pathways. Early trial results are the strongest yet seen for weight loss.
02 How it works
Retatrutide hits three hormone receptors at once. The GLP-1 and GIP effects reduce appetite and slow digestion, as with tirzepatide. The added glucagon effect appears to raise energy use and help the liver burn fat — which is thought to explain the bigger results, and the more noticeable side effects.
03 Common uses
04 Run profile
The same slow ladder as tirzepatide: a gentle first week, then a step up about every four weeks. Because the stomach effects tend to be stronger, a slower climb is worth it here.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
05 Pairs well with
06 What to watch for
The same stomach pattern as tirzepatide but more pronounced, plus some people report an odd tingling or sensitivity of the skin. A slower climb, smaller meals and hydration help. Persistent vomiting, severe abdominal pain or skin symptoms that do not settle need medical attention. Not for anyone with a history of medullary thyroid cancer or MEN2.
07 Evidence & status
InvestigationalIn a 48-week phase 2 trial, the highest dose produced about 24% average weight loss. Larger phase 3 trials are under way.
Investigational — not FDA-approved as of this writing. It is still in late-stage clinical trials.
08 FAQ
Why is it called a triple agonist?
It acts on three receptors — GLP-1, GIP and glucagon — where tirzepatide acts on two and semaglutide on one.
Is the tingling normal?
It has been reported specifically with retatrutide. If it is strong or does not settle, get it checked.
Is it approved anywhere?
Not yet. It is still being studied in clinical trials.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.